Time series analyses of the effect of FDA communications on use of prescription weight loss medications

Obesity

Volumn 22, Issue 3, 2014, Pages 943-949

  Block, Jason P ^a   Choudhry, Niteesh K ^b   Carpenter, Daniel P ^c   Fischer, Michael A ^b   Brennan, Troyen A ^d   Tong, Angela Y ^b   Matlin, Olga S ^d   Shrank, William H ^b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d CVS Caremark   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; DRUG INFORMATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; RISK BENEFIT ANALYSIS; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; COHORT STUDIES; CYCLOBUTANES; DRUG UTILIZATION; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; PHENTERMINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEIGHT LOSS; YOUNG ADULT;

EID: 84895813582     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20596     Document Type: Article

References (35)

1. Colman E,. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005; 143: 380-385.
2. Yanovski SZ,. Pharmacotherapy for obesity-promise and uncertainty. N Engl J Med 2005; 353: 2187-2189.
3. FDA announces withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. 1997.
4. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
5. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
6. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
7. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
8. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm. 2010.
9. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. Available at: http://www.fda.gov/safety/medwatch/ safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm. 2010.
10. FDA drug safety communication: completed safety review of Xenical/Alli (orlistat) and severe liver injury. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. 2010.
11. Cheung A, Sacks D, Dewa CS, et al. Pediatric prescribing practices and the FDA Black-box warning on antidepressants. J Dev Behav Pediatr 2008; 29: 213-215.
12. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170: 96-103.
13. Jacoby JL, Fulton J, Cesta M, et al. After the black box warning: dramatic changes in ED use of droperidol. Am J Emerg Med 2005; 23: 196.
14. Olfson M, Marcus SC, Druss BG,. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65: 94-101.
15. Ricci JR, Coulen C, Berger JE, et al. Prescriber compliance with black box warnings in older adult patients. Am J Manag Care 2009; 15: e103-e108.
16. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15: 369-386.
17. Dusetzina SB, Higashi AS, Dorsey ER, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care 2012; 50: 466-478.
18. Shrank WH, Choudhry NK, Tong A, et al. Warnings without guidance: patient responses to an FDA warning about ezetimibe. Med Care 2012; 50: 479-484.
19. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833.
20. Bolen SD, Clark JM, Richards TM, et al. Trends in and patterns of obesity reduction medication use in an insured cohort. Obesity (Silver Spring) 2009; 18: 206-209.
21. Encinosa WE, Bernard DM, Steiner CA, et al. Use and costs of bariatric surgery and prescription weight-loss medications. Health Aff (Millwood) 2005; 24: 1039-1046.
22. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health; 1998.
23. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
24. Hendricks EJ, Rothman RB, Greenway FL,. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009; 17: 1730-1735.
25. Meridia-sibutramine hydrochloride capsule. Label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020632s034s035lbl.pdf.
26. Meridia-sibutramine hydrochloride monohydrate capsule. Label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020632s032lbl.pdf.
27. Adipex-P. Label. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2012/085128s065lbl.pdf.
28. Cheung BM,. Drug treatment for obesity in the post-sibutramine era. Drug Saf 2011; 34: 641-650.
29. Rothman RB, Hendricks EJ,. Phentermine cardiovascular safety. Am J Emerg Med 2009; 27: 1010-1013.
30. Center for Drug Evaluation and Research. Draft final label, application number: 40276. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/anda/ 98/40276-Phentermine%20Hydrochloride-Prntlbl.pdf.
31. VI-0521 (Qnexa) advisory committee briefing document. FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting. 2012.
32. Lauer MS,. Lemons for obesity. Ann Intern Med 2012; 157: 139-140.
33. FDA approves orlistat for over-the-counter use. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108839.htm. 2007.
34. Lee JS, Sheer JL, Lopez N, et al. Coverage of obesity treatment: a state-by-state analysis of Medicaid and state insurance laws. Public Health Rep 2010; 125: 596-604.
35. Medicare prescription drug benefit manual. Chapter 6-Part D drugs and formulary requirements. Available at: http://www.cms.gov/Medicare/Prescription- Drug-Coverage/PrescriptionDrugCovContra/downloads/Chapter6.pdf. 2010.